TY - JOUR
T1 - Characteristics and predictors of persistent symptoms post-COVID-19 in children and young people
T2 - a large community cross-sectional study in England
AU - Atchison, Christina J.
AU - Whitaker, Matthew
AU - Donnelly, Christl A.
AU - Chadeau-Hyam, Marc
AU - Riley, Steven
AU - Darzi, Ara
AU - Ashby, Deborah
AU - Barclay, Wendy
AU - Cooke, Graham S.
AU - Elliott, Paul
AU - Ward, Helen
N1 - Publisher Copyright:
© 2023 BMJ Publishing Group. All rights reserved.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Objective To estimate the prevalence of, and associated risk factors for, persistent symptoms post-COVID-19 among children aged 5-17 years in England. Design Serial cross-sectional study. Setting Rounds 10-19 (March 2021 to March 2022) of the REal-time Assessment of Community Transmission-1 study (monthly cross-sectional surveys of random samples of the population in England). Study population Children aged 5-17 years in the community. Predictors Age, sex, ethnicity, presence of a pre-existing health condition, index of multiple deprivation, COVID-19 vaccination status and dominant UK circulating SARS-CoV-2 variant at time of symptom onset. Main outcome measures Prevalence of persistent symptoms, reported as those lasting ≥3 months post-COVID-19. Results Overall, 4.4% (95% CI 3.7 to 5.1) of 3173 5-11 year-olds and 13.3% (95% CI 12.5 to 14.1) of 6886 12-17 year-olds with prior symptomatic infection reported at least one symptom lasting ≥3 months post-COVID-19, of whom 13.5% (95% CI 8.4 to 20.9) and 10.9% (95% CI 9.0 to 13.2), respectively, reported their ability to carry out day-to-day activities was reduced € a lot' due to their symptoms. The most common symptoms among participants with persistent symptoms were persistent coughing (27.4%) and headaches (25.4%) in children aged 5-11 years and loss or change of sense of smell (52.2%) and taste (40.7%) in participants aged 12-17 years. Higher age and having a pre-existing health condition were associated with higher odds of reporting persistent symptoms. Conclusions One in 23 5-11 year-olds and one in eight 12-17 year-olds post-COVID-19 report persistent symptoms lasting ≥3 months, of which one in nine report a large impact on performing day-to-day activities.
AB - Objective To estimate the prevalence of, and associated risk factors for, persistent symptoms post-COVID-19 among children aged 5-17 years in England. Design Serial cross-sectional study. Setting Rounds 10-19 (March 2021 to March 2022) of the REal-time Assessment of Community Transmission-1 study (monthly cross-sectional surveys of random samples of the population in England). Study population Children aged 5-17 years in the community. Predictors Age, sex, ethnicity, presence of a pre-existing health condition, index of multiple deprivation, COVID-19 vaccination status and dominant UK circulating SARS-CoV-2 variant at time of symptom onset. Main outcome measures Prevalence of persistent symptoms, reported as those lasting ≥3 months post-COVID-19. Results Overall, 4.4% (95% CI 3.7 to 5.1) of 3173 5-11 year-olds and 13.3% (95% CI 12.5 to 14.1) of 6886 12-17 year-olds with prior symptomatic infection reported at least one symptom lasting ≥3 months post-COVID-19, of whom 13.5% (95% CI 8.4 to 20.9) and 10.9% (95% CI 9.0 to 13.2), respectively, reported their ability to carry out day-to-day activities was reduced € a lot' due to their symptoms. The most common symptoms among participants with persistent symptoms were persistent coughing (27.4%) and headaches (25.4%) in children aged 5-11 years and loss or change of sense of smell (52.2%) and taste (40.7%) in participants aged 12-17 years. Higher age and having a pre-existing health condition were associated with higher odds of reporting persistent symptoms. Conclusions One in 23 5-11 year-olds and one in eight 12-17 year-olds post-COVID-19 report persistent symptoms lasting ≥3 months, of which one in nine report a large impact on performing day-to-day activities.
KW - Adolescent Health
KW - Covid-19
KW - Epidemiology
KW - Infectious Disease Medicine
KW - Paediatrics
UR - http://www.scopus.com/inward/record.url?scp=85152212024&partnerID=8YFLogxK
U2 - 10.1136/archdischild-2022-325152
DO - 10.1136/archdischild-2022-325152
M3 - Article
C2 - 36863848
AN - SCOPUS:85152212024
SN - 0003-9888
VL - 108
SP - E12
JO - Archives of Disease in Childhood
JF - Archives of Disease in Childhood
IS - 7
ER -